Determination of an Optimal Response Cut-Off to Predict Progression-Free Survival(PFS) in Patients(pts) with Well-Differentiated Advanced Pancreatic Neuroendocrine Tumours(pNETs) Treated with Sunitinib(S): An Alternative to the Current RECIST-Response

#1813

Introduction: Sunitinib prolongs PFS in pNET; RECIST defined-partial responses (PR; ≥30% decrease) are low.

Aim(s): We aimed to determine 1) optimal (maximum sensitivity (Se) and specificity (Sp)) RECIST (1.0) response cut-off value to predict progression-free pts at 11 months (m); 2) most informative time-point (highest AUC by ROC analysis and logistic regression) for prediction of benefit (PFS) from S.

Materials and methods: Individual data of pNET pts from the phase II and phase III S trials were analysed (post-hoc).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lamarca A

Authors: Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz H,

Keywords: sunitinib, RECIST, cut-off,